TD Asset Management Inc Has $21.87 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN

TD Asset Management Inc increased its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 289.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,085,823 shares of the company’s stock after buying an additional 806,682 shares during the quarter. TD Asset Management Inc owned 0.22% of Elanco Animal Health worth $21,868,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also added to or reduced their stakes in the business. Hsbc Holdings PLC increased its holdings in Elanco Animal Health by 434.2% in the second quarter. Hsbc Holdings PLC now owns 126,334 shares of the company’s stock valued at $1,801,000 after purchasing an additional 102,686 shares during the period. Norges Bank bought a new stake in shares of Elanco Animal Health in the 2nd quarter valued at about $12,502,000. Amalgamated Bank increased its stake in shares of Elanco Animal Health by 793.7% in the third quarter. Amalgamated Bank now owns 226,580 shares of the company’s stock valued at $4,563,000 after buying an additional 201,226 shares during the period. Independent Advisor Alliance raised its position in shares of Elanco Animal Health by 364.5% during the third quarter. Independent Advisor Alliance now owns 98,025 shares of the company’s stock worth $1,974,000 after acquiring an additional 76,920 shares during the last quarter. Finally, State of Michigan Retirement System bought a new stake in shares of Elanco Animal Health in the 3rd quarter valued at $2,383,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Rajeev A. Modi acquired 4,500 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was purchased at an average cost of $21.33 per share, with a total value of $95,985.00. Following the acquisition, the insider owned 123,082 shares of the company’s stock, valued at approximately $2,625,339.06. This trade represents a 3.79% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction dated Friday, December 12th. The stock was bought at an average cost of $21.30 per share, with a total value of $213,000.00. Following the completion of the purchase, the director owned 131,773 shares of the company’s stock, valued at approximately $2,806,764.90. The trade was a 8.21% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 43,450 shares of company stock worth $937,883 over the last 90 days. Company insiders own 0.89% of the company’s stock.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN opened at $26.35 on Friday. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $27.72. The stock’s 50 day moving average is $24.23 and its 200-day moving average is $21.79. The company has a quick ratio of 1.23, a current ratio of 2.17 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $13.10 billion, a price-to-earnings ratio of -54.90, a PEG ratio of 3.40 and a beta of 1.87.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the previous year, the business posted $0.14 EPS. Elanco Animal Health’s quarterly revenue was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ELAN shares. Wall Street Zen upgraded shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Monday, January 19th. JPMorgan Chase & Co. boosted their price objective on Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, February 19th. Argus raised Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Wednesday, November 19th. Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $24.00 to $30.00 in a research note on Thursday, January 22nd. Finally, KeyCorp increased their price target on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $27.67.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.